The TMPRSS2-ERG fusion is present in approximately 50% of prostate cancers, while fusions with ETS genes ETV1, ETV4, and ETV5 occur in approximately 10%, 2 to 5%, and 1% of cases, respectively (3, 4). This evidence concerns the gene TMPRSS2 and prostate carcinoma.